Announcing the 2024 Endocrinology and Metabolism Fellows!
- November 28, 2023
A Large New Study on Weight Loss Drugs Like Wegovy Has Good News if You’re Looking To Reduce Your Heart Attack RiskSource: Parade
Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology), discusses the improved health outcomes in people who are treated for obesity.
- November 17, 2023
This inaugural event marked the launch of the Cancer Metabolism Initiative (CAMI), which aims to bring together investigators from across the campus to shape the future of cancer metabolism.
- November 16, 2023
Yale Diabetes Research Center Soliciting Grant Applications
- November 15, 2023
Anti-obesity Medication Semaglutide (Wegovy®) Could Benefit Millions of Americans With Obesity and Cardiovascular Disease
The medication has the potential to markedly reduce the risk of heart attacks and other heart-related conditions among millions of Americans with obesity who have also been diagnosed with cardiovascular disease, a Yale study shows.
- November 15, 2023
Welcome New Staff, Faculty, Postdoctoral Associates/Fellows & Postgraduate Associates/Fellows (Nov. 2023)
The Department of Internal Medicine is pleased to welcome the following new faculty, staff members, postgraduate associates / fellows, and postgraduate associates / fellows who joined us in October 2023...
- November 11, 2023Source: Time
Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology), weighs in on the additional benefits of treating obesity.
- November 11, 2023Source: CNBC
Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology), weighs in on a study that showed Wegovy reduced the risk of of serious cardiovascular events in people with obesity and heart disease.
- November 11, 2023Source: Wired
Ania Jastreboff, MD, PhD, talks about how treating obesity improves health outcomes.
- November 08, 2023Source: New York Times
Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology), was principal investigator of a large 72-week study of tirzepatide in 2,539 people with obesity. The drug was approved by the FDA on Wednesday, Nov. 8.